Insulin glargine

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

Retrieved on: 
Thursday, June 2, 2022
Health, FDA, Medical Devices, Diabetes, Clinical Trials, Research, Science, Insulin analog, Company, Research, Knowledge, Prediabetes, Pharmacokinetics, Pharmacology, Physician, FDA, Insulin, Biosimilar, Diabetes, Obesity, Clinical trial, Insulin lispro, Drug development, Civica Rx, AP, Safety, Insulin aspart, Pancreas, Pharmaceutical industry, Insulin glargine, Civica, Profil

Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
  • Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.
  • With its extensive experience and quality track record, Profil is the ideal clinical trial partner for Civica.
  • More information on Civica and its affordable insulin initiative, including commentary from partners and a fact sheet, can be found at https://civicainsulin.org .

The Global Insulin Syringes Market Will Grow to USD 2.1 Billion by 2027, at a CAGR of 4.5% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 20, 2022
Health, General Health, People, Type 2, Insulin, Center, Korea Disease Control and Prevention Agency, Syringe, American Diabetes Association, Obesity, Population, CDC, COVID-19, Adult, WHO, CSII, Ageing, Viatris, Medicine, Incidence, Diabetes, CAGR, US FDA, Hospital, World, Patient, Eli Lilly and Company, Growth, Mortality, Technology, Company, US, Clifton Springs Hospital & Clinic, Public health, USD, Partnership, City, End user, FDA, Eli Lilly, Industry, World Health Organization, Pharmaceutical industry, Borosilicate glass, Lilly, Insulin glargine, Disease, Cipla, Dulaglutide, Insulin lispro

The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period.
  • On the basis of Disease, the insulin syringe market is segmented into Type 1 Diabetes and Type 2 Diabetes.
  • Type 2 Diabetes is expected to account for the largest revenue share in the Insulin Syringes Market by 2020.
  • North America is expected to be the leading region in the Insulin Syringes Market by 2020, with the largest revenue share.

JDRF Announces Support of Civica to Manufacture and Distribute Low-Cost Insulin

Retrieved on: 
Thursday, March 3, 2022
Mayo Clinic, Automated insulin delivery systems, Cranial nerve disease, Critical care, Research, Human, HCA Healthcare, Blue Cross, Industry, Diet, Hospital, Leona, Death, Twitter, Insulin, Eye, Insulin lispro, Civica, Trinity, SSM Health, Insulin aspart, Program, JDRF, Volunteering, Trinity Health, Efficiency, CommonSpirit Health, Intermountain Healthcare, Multimedia, Food, Private sector, Pharmacy, Type 1 diabetes, Kidney, Immune system, Health, Arnold Ventures LLC, BCBS, Pancreas, Blue Cross Blue Shield Association, Pharmaceutical industry, T1D, Transcare EMS, Instagram, Kaiser Permanente, Insulin glargine, Facebook

The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.

Key Points: 
  • The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.
  • "The Civica insulin development project is a tremendous step forward to make insulin accessible for all, regardless of insurance status, and address a national crisis," saidAaron Kowalski, Ph.D., JDRF CEO.
  • Hospital advisorsdoctors and pharmacistsprioritize the essential medicines Civica provides for use in acute and critical care, emergency rooms, and surgery.
  • Civica has since launched CivicaScript, focused on lowering prices at the pharmacy counter and The Civica Foundation, dedicated to fostering philanthropic support for manufacturing and distributing essential medicines.

Adocia announces 2021 fourth quarter financial results

Retrieved on: 
Wednesday, February 23, 2022
IAS, Peptide, Glucagon, Diabetes, Insulin lispro, Industry, Exenatide, Company, IFRS, Safety, Hypoglycemia, Lists of diseases, Protein, Insulin glargine, Obesity, Combo, Patient, Technology, Insulin, Research, Film, Pharmaceutical industry, EUR

The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.

Key Points: 
  • The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.
  • The Company had a cash position of EUR 15.2 million as of December 31, 2021, compared to EUR 28.1 million as of December 31, 2020.
  • Cash consumption for the year 2021 amounts to EUR 19.9 million and stands below last year's level (EUR 22.5 million), on a comparable basis (excluding financing operations).
  • Net financial liabilities (excluding derivative debts impacts) amounted to EUR 33.3 million as of December 31, 2021, compared with EUR 27.3 million as of December 31, 2020.

BUSINESS UPDATE

Retrieved on: 
Thursday, January 20, 2022
Patient, Insulin, Group, US, Growth, Insulin glargine, European Patent Convention, RTU, AIM, Diabetes, European Patent Office, European, Patent, AREC, Pharmaceutical industry

Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing todays therapies to enable healthier lives, provides a business update and announces that its preliminary results for the 12 months ended 31 December 2021 will be issued during the week commencing 25 April 2022.

Key Points: 
  • Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing todays therapies to enable healthier lives, provides a business update and announces that its preliminary results for the 12 months ended 31 December 2021 will be issued during the week commencing 25 April 2022.
  • The Group also continues to drive growth through its portfolio of collaborations across leading pharmaceutical, medical products and biotech companies.
  • Sarah Howell, Chief Executive Officer of Arecor, said: "The continued business progress reflects the strength of our formulation technology and the role it can play in the development of innovative medicines through the enhancement of existing therapeutic products.
  • 2022 has begun with strong momentum across the business and we look forward to further updating the market at our preliminary results."

Investigation Report on China's Insulin Glargine Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Health, Diabetes, COVID-19, CAGR, Growth, Insulin glargine, Research, Patient, Insulin, Diabetes, Gan, Diagnosis, Sanofi, Medical device, Pharmaceutical industry

The "Investigation Report on China's Insulin Glargine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Insulin Glargine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.
  • In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future.
  • 2 Sales of Insulin Glargine in China, 2016-2020
    2.3 Sales of Insulin Glargine by Dosage Form in China, 2016-2020
    3 Analysis of Major Insulin Glargine Manufacturers in China, 2016-2020
    3.3.2 Sales of BASALIN (Gan&Lee Pharmaceuticals Co., Ltd.'s Insulin Glargine) in China
    3.4 Zhuhai United Laboratories Co., Ltd.
    3.4.2 Sales of USLEN (Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine) in China
    4 Prices of Insulin Glargine for Different Manufacturers in China, 2020-2021
    4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)
    5 Prospect of Chinese Insulin Glargine Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005250/en/

Adocia announces its financial calendar for 2022

Retrieved on: 
Thursday, January 6, 2022
Safety, Patient, Obesity, Hypoglycemia, Mission statement, Protein, Combo, Lists of diseases, Glucagon, Diabetes, Insulin glargine, Euronext Paris, GLOBE, Exenatide, Technology, ADOC, Peptide, Industry, Insulin, Insulin lispro, Beauty salon, Pharmaceutical industry

LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.

Key Points: 
  • LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.
  • Publication of revenue for Q1 2022.
  • Publication of mid-year financial statements as of June 30, 2022.
  • In addition to regular meetings with the financial community, investors can also find updated information on the companys website ( www.adocia.com ).

Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations

Retrieved on: 
Thursday, December 30, 2021
Twitter, COVID-19, Private Securities Litigation Reform Act, Upjohn, Combination, Epidemic, Regulation Fair Disclosure, U.S. Securities and Exchange Commission, NASDAQ, Pharmacy, Pfizer, Pandemic, Diabetes, SEC, Multimedia, YouTube, Reg, Adult, Review, Patient, Patent, Security (finance), LinkedIn, Online gambling, Pharmaceutical industry, Viatris, Sanofi, Insulin glargine

(NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.

Key Points: 
  • (NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.
  • These affirmances reinforce the company's continuing efforts to break down barriers to patient access for important medicines such as Semglee through its Global Healthcare Gateway .
  • The Semglee products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, Lantus, allowing for substitution at the pharmacy counter.
  • Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Retrieved on: 
Monday, December 20, 2021
Investigational New Drug, HEC, Food, BLA, FDA, LCI, Company, NYSE, IND, Insulin, Risk, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, PD, Biologics license application, Diabetes, SAHPRA, News, Pharmaceutical industry, Insulin glargine

PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Key Points: 
  • PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
  • If successful, we would anticipate filing the Biologics License Application (BLA) in early 2023 and potentially launching the product by early 2024."
  • Submission of the IND kicks off the final regulatory process before Lannett starts the pivotal trial.
  • The trial site has experience with clinical insulin trials and has been used by other innovator firms for their insulin clinical trials.

Walgreens Prescription Savings Club Offers Steep Savings on Viatris’ Long-Acting Insulin

Retrieved on: 
Thursday, November 18, 2021
Retail, Health, Convenience Store, Diabetes, Managed Care, Pharmaceutical, Biotechnology, Patient, Walgreens Boots Alliance, Centers for Disease Control and Prevention, WBA, Biosimilar, Insulin, Insurance, JAMA, Insulin glargine, GA, Overalls, Technology, United States Department of Health and Human Services, Population, Program, Prescription, Providers, Nasdaq, JAMA Internal Medicine, Adult, FDA, Nice, Pharmacist, Human services, Association, Center, Statistics, Pharmaceutical industry, Health insurance

Walgreens today announced that Viatris long-acting interchangeable Insulin Glargine (insulin glargine-yfgn) injection, co-developed with Biocon Biologics, will be offered through the Walgreens Prescription Savings Club, saving members up to 80 percent off the cash price of comparable long-acting insulins purchased at Walgreens.

Key Points: 
  • Walgreens today announced that Viatris long-acting interchangeable Insulin Glargine (insulin glargine-yfgn) injection, co-developed with Biocon Biologics, will be offered through the Walgreens Prescription Savings Club, saving members up to 80 percent off the cash price of comparable long-acting insulins purchased at Walgreens.
  • Insulin Glargine (insulin glargine-yfgn) will be offered to Walgreens Prescription Savings Club members as a vial for $71.99 and a box of five pens for $84.99.
  • The Walgreens Prescription Savings Club is not insurance but a discount prescription drug program offering savings of up to 80 percent off cash retail prices of prescriptions purchased at participating Walgreens.
  • To learn more and enroll in the Walgreens Prescription Savings Club, visit Walgreens.com/RxSavingsClub or contact a Walgreens pharmacist via phone, in-store or using the Walgreens app.